CM-24
Based on 1 Customer Validation
CM-24 (MK-6018) is a highly selective humanized monoclonal antibody targeting CEACAM1/CD66a. CM-24 binds to the N-terminal domain of CEACAM1, blocks the CEACAM1-CEACAM1 interaction, relieves the co-inhibitory effect on CEACAM1-positive lymphocytes, and enhances the cytotoxic activity of TIL, LAK and NK cells against CEACAM1-positive tumor cells. CM-24 can be used in studies related to tumor immunology, tumor metastasis and thrombosis. For the isotype control of CM-24, refer to Human IgG1 kappa, Isotype Control (HY-P99001).
For research use only. We do not sell to patients.
- Purity : 96.02%
- CAS No.: 1783801-93-3
- Molecular Weight:144.98 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
Isotype
Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
[1]|
CEACAM1 |
In Vitro
CM-24 (MK-6018) (0.1-10 μg/mL; pre-treated for 30 min followed by 24 h co-culture) dose-dependently enhances the cytotoxic activity of human LAK cells against SK-MEL-28 melanoma cells[2].
CM-24 (0.1-10 μg/mL; 30 min pre-treatment followed by 24 h co-culture) enhances the cytotoxic activity of LAK cells against T3M4, SU8686 and PANC2 pancreatic cancer cells as well as H358 and H460 lung cancer cells, and increases the secretion of Granzyme B and IFNγ[2].
CM-24 (20 μg/mL; 1 h) specifically binds to NET structures formed by PMA (HY-18739)-stimulated primary human neutrophils, while no detectable staining is observed with the human IgG4 isotype control[3].
CM-24 (500 μg/mL; 24-48 h) inhibits NETs (20 ng/μL)-induced migration of SK-MEL-28, A549 and AsPC-1 cells by 69.5%, 82.7% and 49.1%, respectively[3].
CM-24 (500 μg/mL; pre-treated for 30 min followed by 2 h of incubation) significantly reduces the adhesion of CEACAM1-positive SK-MEL-28 cells to 4 ng/μL NETs[3].
CM-24 (500 μg/mL; 30 min pre-treatment) reduces platelet aggregation induced by 5 and 10 ng/μL fresh NETs by 70% and 53%, respectively, compared with IgG4 isotype control[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:SK-MEL-28, A549 and AsPC-1 cells
-
Concentration:CM-24: 500 μg/mL; NETs: 20 ng/μL
-
Incubation Time:SK-MEL-28/A549: 24 h; AsPC-1: 48 h
-
Result:Inhibited NET-induced migration by 69.5%, 82.7% and 49.1%, respectively.
-
Cell Line:NETs generated from PMA-stimulated primary human neutrophils
-
Concentration:CM-24: 20 μg/mL; PMA: 100 nM
-
Incubation Time:NET induction: 4 h; CM-24 staining: 1 h
-
Result:Specifically bound NET structures, whereas isotype control showed no detectable staining.
In Vivo
Combination of CM-24 (1-10 mg/kg; i.v.; twice weekly) with melanoma-reactive TIL reduces the median number of lung lesions to 5, 6, 3, and 2, respectively, compared with 45 in the TIL plus control IgG group[2].
CM-24 (25-100 mg/kg; intravenous infusion; once every 2 weeks; 4 doses administered over 6 weeks) causes no treatment-related toxicity, mortality or pathological changes in rhesus monkeys[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Intravenous MEL526 melanoma lung metastasis model with adoptively transferred melanoma-reactive TILs[2]
-
Dosage:1, 3, 6 and 10 mg/kg
-
Administration:CM-24: i.v., twice weekly for 44 days; TILs: i.v., every 10 days
-
Result:Produced TGI values of 84%, 87%, 90% and 93%, respectively; statistical significance was observed at 6 and 10 mg/kg.
-
Animal Model:Intravenous MEL526 melanoma lung metastasis model[2]
-
Dosage:1, 3, 6 and 10 mg/kg
-
Administration:i.v., twice weekly; combined with TILs
-
Result:Reduced median lung lesion counts to 5, 6, 3 and 2, respectively, compared with 45 in the TIL plus control IgG group.
-
Animal Model:TIL receptor-occupancy assessment in lung lesions[2]
-
Dosage:1, 3, 6 and 10 mg/kg
-
Administration:i.v., twice weekly
-
Result:Produced approximately 50% CEACAM1 receptor occupancy at 1 mg/kg and >90% occupancy at 3, 6 and 10 mg/kg.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Application
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized CEACAM1 Protein, Human can bind CM-24. The EC50 for this effect is 3.38 ng/mL. -
Flow cytometric analysis of 1.5X106 HT-29 cells with CM-24 (HY-P990569, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
Chemical Information
-
CAS No. 1783801-93-3
-
Appearance Liquid
-
Molecular Weight 144.98 kDa
-
Color Colorless to light yellow
-
Synonyms
MK-6018
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Research Protocol for Cancer Immunology
Cancer immunology studies how the immune system recognizes, suppresses, edits, or fails to eliminate malignant cells through tumor antigen release, antigen presentation, T-cell priming, immune trafficking, tumor-cell killing, and feedback inhibition in the tumor microenvironment. The cancer-immunity cycle links tumor antigenicity, dendritic-cell priming, CD8+ T-cell infiltration, cytotoxic function, and immune-checkpoint regulation to tumor rejection or immune escape. Immune-checkpoint pathways such as PD-1/PD-L1 and CTLA-4 suppress antitumor T-cell activity and can be therapeutically blocked, but many tumors remain resistant because of poor antigen presentation, weak T-cell infiltration, suppressive myeloid cells, regulatory T cells, and tumor-intrinsic immune-exclusion programs. Unresolved questions include which immune-cell states predict response, how tumor-intrinsic pathways exclude immune cells, how myeloid suppression limits checkpoint blockade, and which combination strategies
-
Orthotopic Cell-Line Xenograft
Orthotopic cell-line xenograft models involve implantation of human cancer cell lines into the anatomically corresponding organ of immunodeficient mice to reproduce tumor growth within a native microenvironment, enabling more clinically relevant tumor behavior compared with subcutaneous models. These models are widely used because orthotopic placement better recapitulates tumor progression, including invasion and metastatic spread, which are often underrepresented in heterotopic implantation systems. Compared with conventional xenografts, orthotopic implantation is described as more technically complex but provides improved simulation of tumor-microenvironment interactions and metastatic behavior, making it particularly valuable for translational oncology research. Surgical orthotopic implantation approaches have been emphasized as enabling faithful reproduction of clinical cancer features, including metastasis and disease progression patterns that align with the tumor’s organ of origi
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
-
Data Sheet (266 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)